[RESEARCH BLOG] · 2026-09-02
Hims & Hers Health, Inc. (HIMS) – Sell‑Flip Signal Amid FDA Crackdown and Legal Scrutiny
By Pierre Brunelle · Founder & Research Lead
Hims & Hers closed at $28.44, down 3.85% on 2026‑09‑01 (Tuesday). The LOPJLB platform has issued a SELL directional signal with a CRISIS market‑regime overlay, assigning the stock a composite score of –5.
Recent News Flow
-
2026‑09‑01 – INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hims & Hers Health, Inc. - HIMS (GlobeNewswire). The filing underscores heightened legal exposure for the company and its board.
-
2026‑09‑01 – Hims & Hers falls after FDA crackdown on unapproved weight‑loss drugs (Proactive Investors). The U.S. Food and Drug Administration intensified enforcement actions against Hims & Hers, targeting unapproved weight‑loss medications marketed through the platform.
-
2026‑08‑31 – Hims Enters Australia, Marking First Expansion into the Asia‑Pacific Market (GuruFocus). The article details the launch of GLP‑1 weight‑loss drugs and a suite of men’s‑health treatments.
-
2026‑08‑31 – Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide (Business Wire).
-
2026‑08‑31 – Hims Enters Australia, Marking First Expansion into the Asia‑Pacific Market (Business Wire).
-
2026‑08‑31 – Hims & Hers offers GLP‑1 weight‑loss drugs, men's health treatments in Australia (Reuters).
-
2026‑08‑31 – Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) to Contact the Firm to Learn About Their Legal Rights (Newsfile Corp).
-
2026‑08‑31 – Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) (GlobeNewswire).
Fundamentals and Valuation
Hims & Hers operates a digital health platform that connects consumers with licensed clinicians for prescription and wellness services. The company’s financial profile remains volatile, reflecting a rapid growth trajectory tempered by profitability challenges.
Valuation snapshot (as of latest filing):
| Metric | Value |
|---|---|
| P/E (TTM) | -46.62 |
| Forward P/E | 89.96 |
| P/B | 20.34 |
| EV/EBITDA | -95.28 |
| PEG | 2.69 |
| ROIC | -18.02% |
| ROE | -30.03% |
| ROA | -3.91% |
| Gross margin | 64.68% |
| Operating margin | -3.59% |
| Net margin | -5.51% |
| Debt/Equity | 477.1 |
The trailing twelve‑month (TTM) price‑to‑earnings ratio of ‑46.62 reflects a loss‑making base, while the forward P/E of 89.96 signals that analysts expect earnings to turn positive but at a steep valuation multiple. The enterprise‑value‑to‑EBITDA ratio of ‑95.28 similarly underscores negative EBITDA, a byproduct of aggressive expansion and high operating costs.
Margins have been improving on a relative basis. Gross profit margin rose from 73.58 % in 2020 to a peak of 81.99 % in 2023, before settling at 79.45 % in 2024 and 73.84 % in 2025. Operating margins, however, remain thinly negative, moving from ‑10.18 % (2020) to ‑3.38 % (2023) and finally turning modestly positive at 4.19 % (2024) and 4.50 % (2025). Net margins followed a comparable path, shifting from ‑12.18 % (2020) to ‑2.70 % (2023) and achieving 8.54 % (2024) before easing to 5.47 % (2025).
Revenue has accelerated dramatically, climbing from $148.8 M in 2020 to $2.35 B in 2025, a compound annual growth rate (CAGR) exceeding 70 % over the six‑year span. Earnings per share (EPS) have moved from a loss of ‑$0.51 (2020) to a modest profit of $0.57 (2025), indicating that the firm is approaching breakeven on a per‑share basis. Free cash flow, once deeply negative, turned positive in 2023 ($46.99 M) and continued to improve, reaching $73.96 M in 2025.
Return on equity (ROE) swung from a healthy 12.33 % (2020) to a deep negative ‑30.03 % in the most recent period, reflecting the impact of debt‑financed growth and the recent earnings volatility. The debt‑to‑equity ratio of 477.1 signals a heavily leveraged balance sheet, a risk factor amplified by the ongoing FDA scrutiny and pending litigation.
Analyst consensus remains cautious: the median price target is $30.20, only modestly above the current market price, and the prevailing recommendation is Hold. The growth score of 34.00 and quality score of 28.10 place Hims & Hers in the Growth Compounder archetype, indicating that the market still perceives upside potential if the firm can sustain its top‑line momentum while stabilizing margins.
ETF Ownership
Hims & Hers is held by a concentrated set of healthcare‑focused exchange‑traded funds. The top twelve ETF holders collectively own a significant portion of the float, which can magnify price movements when these funds rebalance.
| ETF (Ticker) | Weight % |
|---|---|
| EDOC | 5.74% |
| THNR | 4.58% |
| HEAL | 3.86% |
| FDHT | 2.60% |
| IBUY | 2.48% |
| EKG | 2.34% |
| XHS | 1.75% |
| PTH | 1.60% |
| BUZZ | 1.47% |
| RFG | 1.03% |
| IHF | 0.89% |
| LGHT | 0.58% |
The presence of EDOC (5.74 % weight) and THNR (4.58 % weight) underscores that specialist digital‑health and telemedicine funds have sizable stakes. In a crisis‑regime environment, any shift in these funds’ allocations—whether due to risk‑off sentiment or portfolio rebalancing—could exacerbate price volatility for HIMS.
LOPJLB Signal Read
The LOPJLB engine flags Hims & Hers with a SELL directional signal, reflecting a CRISIS market regime that has persisted for three days. The composite performance score of 33.60 and quality fund score of 28.10 suggest that while the stock exhibits growth‑oriented characteristics, its underlying fundamentals are under pressure.
- Directional Signal: SELL
- Market Regime: CRISIS (3‑day streak)
- Composite Score (PERF): 33.60
- Quality Score (FUND): 28.10
- Archetype: Growth Compounder
Investors can explore the interactive chart above for a visual overlay of the sell‑flip trigger, and review the full methodological framework at the LOPJLB methodology page.
What’s Next?
The convergence of regulatory headwinds, legal investigations, and a heavily leveraged balance sheet places Hims & Hers in a precarious position. The recent FDA crackdown on unapproved weight‑loss drugs threatens to curtail a high‑margin revenue stream that the company has been counting on for near‑term profitability. Simultaneously, the Pomerantz and Berger Montague investigations raise governance concerns that could prompt further shareholder activism or even board changes.
On the upside, the Australian launch expands the addressable market and diversifies geographic exposure. If the company can successfully navigate the regulatory landscape in the United States while scaling its GLP‑1 and men’s‑health offerings abroad, revenue could continue its steep trajectory. However, the current Debt/Equity ratio of 477.1 limits financial flexibility, and any deterioration in cash flow could force the firm to raise capital under unfavorable terms, diluting existing shareholders.
Given the SELL signal and CRISIS regime, market participants should monitor:
- Regulatory outcomes – FDA enforcement actions and any subsequent product recalls or labeling changes.
- Legal developments – Progress of the Pomerantz and Berger Montague investigations, including any settlements or court rulings.
- Cash‑flow trends – Quarterly free‑cash‑flow reports to gauge whether the recent positive trajectory is sustainable.
- ETF rebalancing – Potential shifts in holdings by the top ETFs, especially EDOC and THNR, which could amplify price swings.
Further Research
For a deeper dive into Hims & Hers’ valuation metrics, earnings history, and the full suite of LOPJLB overlays, visit the dedicated stock page: https://www.lopjlb.com/stock/HIMS.
If earnings‑call transcripts become available, the LOPJLB earnings‑call analysis will be posted at https://www.lopjlb.com/stock/HIMS/earnings.md.
To screen for other healthcare stocks with similar signal profiles, explore the LOPJLB screener at https://www.lopjlb.com/screener.
The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.